Last reviewed · How we verify
Arbutyne (ARBUTIN)
At a glance
| Generic name | ARBUTIN |
|---|---|
| Drug class | Adenosine Receptor Agonist [EPC] |
| Target | Tyrosinase, Polyphenol oxidase 2, Tyrosinase |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians (NA)
- Trial Evaluating Both Tolerability and Improvement for Signs of Facial Photoaging, Discoloration, and Texture in Adult Females of All Skin Types by Combining a Placebo Moisturizer and Non-ablative Laser. (PHASE4)
- The Efficacy of Topical Serum X for Skin Brightening (NA)
- Efficacy of Melanostop Peeling for Improvement of Melasma (NA)
- Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma (PHASE2,PHASE3)
- Safety Evaluation of β-arbutin in Healthy Human Subjects (PHASE1)
- Treatment of Chronic Bacterial Prostatitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arbutyne CI brief — competitive landscape report
- Arbutyne updates RSS · CI watch RSS